BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12141246)

  • 1. Valganciclovir: a new treatment for cytomegalovirus retinitis.
    Marco M
    BETA; 2002; 15(1):19-21. PubMed ID: 12141246
    [No Abstract]   [Full Text] [Related]  

  • 2. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis.
    Martin DF; Sierra-Madero J; Walmsley S; Wolitz RA; Macey K; Georgiou P; Robinson CA; Stempien MJ;
    N Engl J Med; 2002 Apr; 346(15):1119-26. PubMed ID: 11948271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus retinitis: new developments in prophylaxis and therapy.
    Jacobson MA
    AIDS Clin Rev; 1997-1998; ():249-69. PubMed ID: 9305451
    [No Abstract]   [Full Text] [Related]  

  • 5. CMV retinitis trial expanding.
    Vazquez E
    Posit Aware; 1998; 9(1):16. PubMed ID: 11364995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drugs for treating CMV. Valcyte, an oral compound, expands the treatment options for people with CMV retinitis.
    Eagan L
    Posit Living; 2001; 10(6):13. PubMed ID: 11702748
    [No Abstract]   [Full Text] [Related]  

  • 7. Valganciclovir hydrochloride.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2246-7. PubMed ID: 11763801
    [No Abstract]   [Full Text] [Related]  

  • 8. Valganciclovir hydrochloride (Valcyte): a new antiviral agent.
    Weiskittel P
    Nephrol Nurs J; 2003 Feb; 30(1):93-5. PubMed ID: 12674959
    [No Abstract]   [Full Text] [Related]  

  • 9. Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
    Jabs DA
    Infect Agents Dis; 1995 Sep; 4(3):131-42. PubMed ID: 8548191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subretinal hemorrhage associated with cytomegalovirus retinitis in a patient without concurrent thrombocytopenia.
    Beck AP; Ravage ZB; Richmond CA
    Retina; 2004 Aug; 24(4):611-3. PubMed ID: 15300084
    [No Abstract]   [Full Text] [Related]  

  • 11. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis.
    Lalezari J; Lindley J; Walmsley S; Kuppermann B; Fisher M; Friedberg D; Lalonde R; Matheron S; Nieto L; Torriani FJ; Van Syoc R; Sutton MA; Buhles W; Stempien MJ;
    J Acquir Immune Defic Syndr; 2002 Aug; 30(4):392-400. PubMed ID: 12138345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegaloviral retinitis.
    Tripathy K; Venkatesh P; Chawla R
    Natl Med J India; 2016; 29(1):35. PubMed ID: 27492038
    [No Abstract]   [Full Text] [Related]  

  • 13. Local therapy of CMV retinitis: a new therapeutical approach.
    Fuchs AV; Scheider A; Klauss V; Kampik A
    Dev Ophthalmol; 1997; 29():64-8. PubMed ID: 9413696
    [No Abstract]   [Full Text] [Related]  

  • 14. Valganciclovir therapy for immune recovery uveitis complicated by macular edema.
    Raj A
    Am J Ophthalmol; 2005 Jan; 139(1):216-7; author reply 217. PubMed ID: 15652864
    [No Abstract]   [Full Text] [Related]  

  • 15. Valganciclovir: an advance in cytomegalovirus therapeutics.
    Cocohoba JM; McNicholl IR
    Ann Pharmacother; 2002 Jun; 36(6):1075-9. PubMed ID: 12022911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the Food and Drug Administration.
    Schwetz BA
    JAMA; 2001 Jun; 285(21):2705. PubMed ID: 11386912
    [No Abstract]   [Full Text] [Related]  

  • 17. New treatment options for CMV retinitis in AIDS.
    Lalezari JP
    Adv Nurse Pract; 1997 Apr; 5(4):45-9, 83. PubMed ID: 9459896
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic decisions: informed choices in a changing clinical environment.
    Holland GN
    Am J Ophthalmol; 1999 Mar; 127(3):327-8. PubMed ID: 10088744
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapy for cytomegalovirus retinitis: still no silver lining.
    Young LH
    JAMA; 1996 Jan; 275(2):149-50. PubMed ID: 8531313
    [No Abstract]   [Full Text] [Related]  

  • 20. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
    Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
    J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.